For decades, "a glass of red wine a day is good for your heart" was treated as settled science, backed by studies showing lower cardiovascular mortality in light drinkers compared with non-drinkers — the so-called J-curve. The largest, most methodologically rigorous analyses of alcohol and health outcomes ever conducted have since undercut that story substantially. It's worth understanding what these studies actually found, and where the real nuance is.
The GBD 2016 Alcohol Collaborators pooled data from 694 sources on alcohol consumption and 592 prospective and retrospective studies on alcohol-related risk across 195 countries and territories, making it one of the largest evidence syntheses on the topic ever assembled (Griswold MG, et al., The Lancet, 2018). Their headline finding: when health outcomes are combined across the full range alcohol affects — not just cardiovascular disease, but cancers, injuries, infectious disease, and more — the level of consumption that minimizes total health loss is zero.
That doesn't mean every drink carries equal individual risk, or that occasional moderate drinking produces a dramatic health penalty for any one person. It means that, at a population level, there is no threshold of regular consumption below which total risk is lower than not drinking at all.
A follow-up Global Burden of Disease analysis modeling risk by age and region (GBD 2020, The Lancet, 2022) found that a J-shaped curve — where light drinkers showed modestly lower risk than non-drinkers — held specifically for ischemic heart disease. That is a real, replicated finding, and it's likely the origin of the popular "wine is heart-healthy" narrative.
But when the same analysis looked at other outcomes — cancers in particular — risk increased with any level of consumption, with no protective dip at low intake. Because cardiovascular disease research got outsized public attention relative to cancer risk, the heart-specific J-curve became the popular takeaway even though it doesn't generalize to overall health risk.
Part of why older observational studies showed non-drinkers with worse outcomes than light drinkers is a well-documented selection effect: many "non-drinker" comparison groups in older cohorts included former drinkers who quit due to declining health, illness, or medication — dragging down the apparent health of the "no alcohol" group for reasons that had nothing to do with alcohol itself. Studies that carefully separate lifelong abstainers from former drinkers tend to show a smaller or absent protective effect at the low end.
If you don't drink, there's no longevity reason to start. "Drinking a little for your heart" is not supported once cancer and other outcomes are weighed alongside cardiovascular risk.
If you drink, less is consistently better than more. Risk rises with quantity for most outcomes measured in these analyses — there's no evidence-based "safe ceiling" below which risk stops accumulating, but the dose-response relationship means cutting back still meaningfully reduces cumulative exposure.
Consider what you're optimizing for. If cardiovascular risk is your primary concern and you already drink lightly, the ischemic heart disease data is more favorable than the cancer data. If minimizing total mortality and cancer risk is the goal, zero is where the aggregate evidence points.
Liver support for regular drinkers. If you drink and aren't planning to stop, milk thistle (silymarin) is one of the more studied liver-support supplements — it doesn't offset alcohol's mortality risk, but it's a reasonable adjunct alongside cutting back.
Browse Milk Thistle on Amazon →NAD+ support. Chronic alcohol intake depletes NAD+, a coenzyme central to cellular energy and repair. NAD+ precursor supplements (NMN/NR) are a popular longevity-stack addition for people looking to offset some of that metabolic load.
Browse NAD+ Supplements on Amazon →A 28-day fillable sleep log built around the seven levers that actually move sleep, so you test one per week and see what it did.
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.